

Announcement

Biocon Biologics Moves into New North American Headquarters in Bridgewater, New Jersey

BRIDGEWATER, New Jersey, July 16, 2024

Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company, today announced that the company has established its first North American headquarters in Bridgewater, New Jersey. This brings the company into a new 9,624-square-foot (sf) office located at 685 Route 202/206 within the state’s biopharma corridor. The new headquarters will house both commercial and administrative functions for the organization.

Josh Salsi, Head of North America, Biocon Biologics, said: “We are excited to establish our first North America headquarters within the hub of the biopharma sector of New Jersey where we can leverage the strong life sciences ecosystem of innovation, talent, and excellent quality of life for our employees and be well-positioned for future growth.”

Biocon Limited, the parent company of Biocon Biologics, operates a [manufacturing facility in Cranbury](#) as well as an office in Iselin, New Jersey.

About Biocon Biologics Limited:

Biocon Biologics Ltd. (BBL), a subsidiary of Biocon Ltd., is a unique, fully integrated, global biosimilars company committed to transforming healthcare and transforming lives by enabling affordable access to high quality biosimilars for millions of patients worldwide. It is leveraging cutting-edge science, innovative tech platforms, global scale manufacturing capabilities and world-class quality systems to lower costs of biological therapeutics while improving healthcare outcomes.

BBL has integrated the acquired global biosimilars business of its long-standing partner Viatrix, which is a historic milestone in its value creation journey. Biocon Biologics has commercialized eight biosimilars in key emerging markets and advanced markets like U.S., Europe, Australia, Canada, and Japan. The Company has a pipeline of 20 biosimilar assets across diabetology, oncology, immunology, ophthalmology, and other non-communicable diseases. It has many ‘firsts’ to its credit in the biosimilars industry. As part of its environmental, social and governance (ESG) commitment, BBL is advancing the health of patients, people, and the planet to achieve key UN Sustainable Development Goals (SDGs). Website: www.bioconbiologics.com; Follow us on Twitter: @BioconBiologics and LinkedIn: [Biocon Biologics](#) for company updates.



Media Contact:

Lance Longwell

Public Relations Lead – Advanced Markets

+1 857 270 4391

lance.longwell@biocon.com